What is the 13F Pro Quality Score for EW?

13F Pro ranks Edwards Lifesciences Corp (EW) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View EW's current score at https://13fpro.ai/company/EW (free sign-up required for the full ranking).

Where does 13F Pro source EW data?

All Edwards Lifesciences Corp fundamentals and ownership data come directly from SEC EDGAR. Edwards Lifesciences Corp files with the SEC under CIK 1099800. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is EW in?

Edwards Lifesciences Corp (EW) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives EW's revenue?

Per Edwards Lifesciences Corp's latest 10-Q filed with the SEC on 2026-08-04, the biggest revenue drivers are: Transcatheter Aortic Valve Replacement (TAVR) ($1,258.3M, +11.3% YoY); Surgical ($284.1M, +6.5% YoY); Transcatheter Mitral and Tricuspid Therapies (TMTT) ($198.6M, +47.7% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/EW.

What are EW's largest expenses?

Edwards Lifesciences Corp's latest 10-Q reports these as the largest expense items: Selling, general, and administrative expenses ($561.2M); Cost of sales ($392.4M); Research and development expenses ($278.9M). Sourced directly from SEC EDGAR filing text for Q2 2026 (quarter ended June 30, 2026).

How often is EW research updated on 13F Pro?

EW's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Edwards Lifesciences Corp(EW)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSElarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 1099800 EW stock profile & AI dashboard →

13F Pro Quality Score

69.4/100

Rank #267 of 2,961 stocksTOP 10%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

64.8/100

Profitability

64.4/100

Balance Sheet

78.6/100

Earnings Quality

79.4/100

Free Cash Flow

75.3/100

Institutional Flow

95.1/100

Revenue Scale

81.6/100

Dilution Risk

35.6/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why EW Scores 69/100

exact factor attribution · 2026-09-11

EW's composite is driven by scale and free cash flow, held back by earnings growth. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Scale

+4.7 pts

82th pct

Free cash flow

+3.8 pts

75th pct

Revenue growth

+3.0 pts

65th pct

Earnings quality

+2.9 pts

79th pct

Capital efficiency

+2.9 pts

79th pct

Institutional flow

+2.3 pts

95th pct

Profitability

+2.2 pts

64th pct

Shareholder dilution

-0.7 pts

36th pct

Earnings growth

-1.5 pts

19th pct

Latest change (2026-08-04): 68 → 63 · ↓ Profit margin 80→68; ↓ Revenue growth 66→54; despite ↑ Earnings growth 6→21

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

EW Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Edwards Lifesciences Corp (EW), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores EW at 69.4/100 on a 32-signal composite quality model, placing it at rank #267 of 2,961 stocks — the top 10% of the AI-ranked universe. EW scores in the top quartile across institutional flow (95.1), revenue scale (81.6), earnings quality (79.4). Shareholder dilution risk is elevated at 35.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Edwards Lifesciences Corp reports quarterly revenue of $1.7B, net income of $241.9M, free cash flow of $585.0M. Top institutional holders of EW by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. EW trades on the NYSE exchange and files with the SEC under CIK 1099800. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EW daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Edwards Lifesciences Corp directly from SEC EDGAR. Edwards Lifesciences Corp's 13F Pro composite quality score has ranged between 48 and 77 since 2021, currently 69.4 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about Edwards Lifesciences Corp

Quirks, history, and lore behind EW — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · large-cap · listed on NYSE · headquartered in Southern California.
2
The Numbers
Annual revenue around $6 billion, with operating margins that make most of healthcare jealous — because when your products go inside a beating heart, pricing power is real.
3
The History
Founded in 1958 as a spinoff from Baxter International, it planted its flag early in the then-tiny field of devices designed to keep the cardiovascular system from giving up on you.
4
The Secret
Its core technology is the transcatheter heart valve — a replacement valve delivered through a catheter rather than open-chest surgery, which it helped pioneer and still dominates globally.
5
The Lore
It won a landmark patent lawsuit against Medtronic worth over a billion dollars, one of the largest verdicts in medical device history — turns out the heart valve business is worth fighting for.
6
The Giveaway
Named after a pioneering heart surgeon, its flagship TAVR valves have been implanted in hundreds of thousands of patients who would otherwise have faced open-heart surgery — or nothing at all.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving EW's Business? Latest 10-Q Breakdown

✓ 28/28 datapoints verified

AI-extracted from Edwards Lifesciences Corp's 10-Q filed 2026-08-04 — Q2 2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Q2 net sales rose 13.6% to $1,741.0M, but net income fell to $241.4M as the effective tax rate jumped to 53.6% on a $188.2M valuation allowance.

Biggest Revenue Drivers

Transcatheter Aortic Valve Replacement (TAVR)$1,258.3M+11.3% YoY

Higher sales of the SAPIEN 3 Ultra RESILIA valve in the United States, Europe, and Japan

Surgical$284.1M+6.5% YoY

Higher sales of INSPIRIS RESILIA, MITRIS RESILIA, and KONECT RESILIA in the United States and Europe

Biggest Revenue Drivers

Total revenue: $1,741.0M+13.6% YoY

Transcatheter Aortic Valve Replacement (TAVR)$1,258.3M+11.3% YoY

Higher sales of the SAPIEN 3 Ultra RESILIA valve in the United States, Europe, and Japan

Surgical$284.1M+6.5% YoY

Higher sales of INSPIRIS RESILIA, MITRIS RESILIA, and KONECT RESILIA in the United States and Europe

Transcatheter Mitral and Tricuspid Therapies (TMTT)$198.6M+47.7% YoY

Higher sales of PASCAL, EVOQUE, and SAPIEN M3 systems in the United States and Europe

Largest Expense Items

Selling, general, and administrative expenses$561.2M

Higher headcount related expenses and commercial activities; currency added $6.0 million

Cost of sales$392.4M

Increased with sales growth; partially offset by lower manufacturing expenses

Research and development expenses$278.9M

Increased investments in implantable heart failure management and advanced technology innovation

Certain litigation expenses$6.3M

Legal proceedings, intellectual property litigation and tax litigation, down from $15.5 million

Margins: Gross profit rose to $1,348.6M on sales growth, but gross margin declined roughly 0.7 percentage points from foreign currency rate fluctuations, including hedge settlements, partly offset by lower manufacturing expenses.

Watch Items from the Filing

Effective tax rate was 53.6% versus 16.1% a year ago, chiefly a $188.2 million valuation allowance after California legislation limited research and development credit carryovers.
IRS Final NOPAs propose U.S. taxable income increases of $625.3M, $530.7M, and $683.6M for 2018-2020, with 40% transfer pricing penalties expected in Q3 2026.
Recorded a $40.0 million impairment in the quarter on a terminated VIE option agreement; year-to-date impairments total $163.6 million.
Japan segment net sales were $96.4 million, up only 1.1% year over year, versus 12.8% U.S. and 16.2% Europe growth.
No customer represented 10% or more of total net sales; company holds $2.9 billion cash and $1.5 billion remaining repurchase authorization.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$1.7B

Net Income

Q2 2026

$241.9M

Free Cash Flow

Q2 2026

$585.0M

ROIC

Q2 2026

18.3%

D/E Ratio

Q2 2026

0.06

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+11.5% YoY

$6.07BFY 2025

FY22 $4.46BFY23 $5.01BFY24 $5.44BFY25 $6.07B

Net Income

-74.3% YoY

$1.07BFY 2025

FY22 $1.52BFY23 $1.40BFY24 $4.17BFY25 $1.07B

Operating Income

-8.3% YoY

$1.26BFY 2025

FY22 $1.50BFY23 $1.31BFY24 $1.38BFY25 $1.26B

EPS (Diluted)

-73.7% YoY

$1.83FY 2025

FY22 $2.44FY23 $2.30FY24 $6.97FY25 $1.83

Total Assets

+4.9% YoY

$13.70BFY 2025

FY22 $8.29BFY23 $9.36BFY24 $13.06BFY25 $13.70B

Total Debt

+0.1% YoY

$598.3MFY 2025

FY22 $596.3MFY23 $597.0MFY24 $597.7MFY25 $598.3M

Op. Cash Flow

+194.2% YoY

$1.60BFY 2025

FY22 $1.22BFY23 $895.8MFY24 $542.3MFY25 $1.60B

Free Cash Flow

+360.5% YoY

$1.33BFY 2025

FY22 $973.6MFY23 $642.8MFY24 $289.9MFY25 $1.33B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$6.07B +11.5%	$5.44B +8.6%	$5.01B +12.2%	$4.46B -14.7%	$5.23B +19.3%	$4.39B
Net Income	$1.07B -74.3%	$4.17B +197.7%	$1.40B -7.9%	$1.52B +1.3%	$1.50B	—
Operating Income	$1.26B -8.3%	$1.38B +5.3%	$1.31B -12.6%	$1.50B -11.4%	$1.69B +88.3%	$897.6M
EPS (Diluted)	$1.83 -73.7%	$6.97 +203.0%	$2.30 -5.7%	$2.44 +2.5%	$2.38 +83.1%	$1.30
Total Assets	$13.70B +4.9%	$13.06B +39.4%	$9.36B +12.9%	$8.29B -2.5%	$8.50B +17.5%	$7.24B
Total Debt	$598.3M +0.1%	$597.7M +0.1%	$597.0M +0.1%	$596.3M +0.1%	$595.7M +0.1%	$595.0M
Operating Cash Flow	$1.60B +194.2%	$542.3M -39.5%	$895.8M -26.5%	$1.22B -29.7%	$1.73B +64.3%	$1.05B
Free Cash Flow	$1.33B +360.5%	$289.9M -54.9%	$642.8M -34.0%	$973.6M -30.8%	$1.41B +117.3%	$647.3M

Get alerted when EW's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Edwards Lifesciences Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of EW

BlackRock, Inc.
$5.3B58,789,433 sh
VANGUARD CAPITAL MANAGEMENT LLC
$3.4B37,615,952 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$2.4B26,411,402 sh
STATE STREET CORP
$2.4B26,321,940 sh
JPMORGAN CHASE & CO
$2.1B22,783,175 sh
WELLINGTON MANAGEMENT GROUP LLP
$1.5B16,827,967 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.4B15,437,251 sh
Bank of New York Mellon Corp
$1.3B14,084,483 sh
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt
$1.2B13,002,965 sh
Ninety One UK Ltd
$1.1B12,337,502 sh

Fund	Value	Shares
BlackRock, Inc.	$5.3B	58,789,433
VANGUARD CAPITAL MANAGEMENT LLC	$3.4B	37,615,952
VANGUARD PORTFOLIO MANAGEMENT LLC	$2.4B	26,411,402
STATE STREET CORP	$2.4B	26,321,940
JPMORGAN CHASE & CO	$2.1B	22,783,175
WELLINGTON MANAGEMENT GROUP LLP	$1.5B	16,827,967
GEODE CAPITAL MANAGEMENT, LLC	$1.4B	15,437,251
Bank of New York Mellon Corp	$1.3B	14,084,483
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt	$1.2B	13,002,965
Ninety One UK Ltd	$1.1B	12,337,502

Companies Similar to EW

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

SYK

STRYKER CORP

AI score

Very similar · 28 shared holders

PRIMECAP MANAGEMENT CO/CA/NORDEA INVESTMENT MANAGEMENT AB SEB Asset Management AB

VRTX

VERTEX PHARMACEUTICALS INC / MA

AI score

Very similar · 37 shared holders

BAILLIE GIFFORD & CO National Pension Service SEB Asset Management AB

ABT

ABBOTT LABORATORIES

AI score

Very similar · 36 shared holders

WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST Holocene Advisors, LP Ninety One UK Ltd

REGN

REGENERON PHARMACEUTICALS, INC.

AI score

Very similar · 31 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC NORDEA INVESTMENT MANAGEMENT AB National Pension Service

IQV

IQVIA HOLDINGS INC.

AI score

Very similar · 21 shared holders

Artisan Partners Limited Partnership National Pension Service NORDEA INVESTMENT MANAGEMENT AB

JNJ

JOHNSON & JOHNSON

AI score

Very similar · 34 shared holders

Ninety One UK Ltd WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST NORDEA INVESTMENT MANAGEMENT AB

IDXX

IDEXX LABORATORIES INC /DE

AI score

Very similar · 31 shared holders

Liontrust Investment Partners LLP BAILLIE GIFFORD & CO Holocene Advisors, LP

BMY

BRISTOL MYERS SQUIBB CO

AI score

Very similar · 35 shared holders

PRIMECAP MANAGEMENT CO/CA/NORDEA INVESTMENT MANAGEMENT AB SEB Asset Management AB

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put EW on your watchlist

Track score changes the day Edwards Lifesciences Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is EW a good stock to buy?

13F Pro's AI-powered analysis of Edwards Lifesciences Corp (EW) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for EW are available on the EW stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. EW is classified as a large company.

Which hedge funds own EW?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling EW. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Edwards Lifesciences Corp's investment landscape.